Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of TRN-157 in Healthy Subjects
NCT02133339Phase 1Completed
- Sponsor
- Theron Pharmaceuticals
- Start
- May 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing TRN-157 with Placebo (2 arms). Primary endpoint: Safety and tolerability as determined by number of subjects with adverse events at 1 week. Started May 2014; status: completed.
02
Drugs
trn-157
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02133339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02133339.